S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
What does consumer price index measure?
Last chance to set up your portfolio for OPEC cuts
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
What does consumer price index measure?
Last chance to set up your portfolio for OPEC cuts
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
What does consumer price index measure?
Last chance to set up your portfolio for OPEC cuts
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
What does consumer price index measure?
Last chance to set up your portfolio for OPEC cuts

ANI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANIP)

$48.72
-1.24 (-2.48%)
(As of 12/6/2023 ET)
Compare
Today's Range
$48.39
$50.24
50-Day Range
$48.72
$65.43
52-Week Range
$36.54
$65.89
Volume
133,033 shs
Average Volume
129,564 shs
Market Capitalization
$995.84 million
P/E Ratio
93.69
Dividend Yield
N/A
Price Target
$71.67

ANI Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
47.1% Upside
$71.67 Price Target
Short Interest
Healthy
1.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.48
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$6.13 M Sold Last Quarter
Proj. Earnings Growth
-11.73%
From $3.58 to $3.16 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

55th out of 957 stocks

Drug Manufacturers - Specialty & Generic Industry

2nd out of 11 stocks


ANIP stock logo

About ANI Pharmaceuticals Stock (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANIP Stock Price History

ANIP Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
A Boring Biopharma Can Be a Good Bet
ANI Pharmaceuticals Inc ANIP
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
ANI Pharmaceuticals Turns To Q3 Profit, Raises Full-year Outlook
Expert Ratings for ANI Pharmaceuticals
See More Headlines
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/14/2024

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
Employees
600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$71.67
High Stock Price Target
$73.00
Low Stock Price Target
$70.00
Potential Upside/Downside
+47.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-47,900,000.00
Pretax Margin
2.94%

Debt

Sales & Book Value

Annual Sales
$316.39 million
Cash Flow
$3.89 per share
Book Value
$17.92 per share

Miscellaneous

Free Float
14,613,000
Market Cap
$995.84 million
Optionable
Optionable
Beta
0.88
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Nikhil  LalwaniMr. Nikhil Lalwani (Age 45)
    President, CEO & Director
    Comp: $1.31M
  • Mr. Stephen P. CareyMr. Stephen P. Carey (Age 52)
    Senior VP of Finance & CFO
    Comp: $751k
  • Mr. James G. Marken (Age 60)
    Senior Vice President of Operations & Product Development
    Comp: $673.23k
  • Mr. Christopher K. Mutz (Age 51)
    Head of Rare Disease
    Comp: $565.17k
  • Mr. Ori Gutwerg (Age 49)
    Senior Vice President of Generics
    Comp: $623.89k
  • Mr. Muthusamy Shanmugam MS R.Ph. (Age 55)
    Head of R&D, COO of Novitium Operations & Director
  • Ms. Meredith W. Cook (Age 49)
    Senior VP, General Counsel & Corporate Secretary
  • Mr. Chad Gassert (Age 47)
    Senior Vice President of Corporate Development & Strategy
  • Ms. Krista L. Davis (Age 50)
    Chief Human Resources Officer
  • Ms. Elizabeth Powell J.D.
    Chief Compliance Officer & Head of Legal of Rare Disease














ANIP Stock Analysis - Frequently Asked Questions

Should I buy or sell ANI Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings
or view top-rated stocks.

What is ANI Pharmaceuticals' stock price target for 2024?

3 Wall Street research analysts have issued 1-year target prices for ANI Pharmaceuticals' stock. Their ANIP share price targets range from $70.00 to $73.00. On average, they predict the company's stock price to reach $71.67 in the next twelve months. This suggests a possible upside of 47.1% from the stock's current price.
View analysts price targets for ANIP
or view top-rated stocks among Wall Street analysts.

How have ANIP shares performed in 2023?

ANI Pharmaceuticals' stock was trading at $40.23 on January 1st, 2023. Since then, ANIP shares have increased by 21.1% and is now trading at $48.72.
View the best growth stocks for 2023 here
.

Are investors shorting ANI Pharmaceuticals?

ANI Pharmaceuticals saw a decline in short interest in November. As of November 15th, there was short interest totaling 376,800 shares, a decline of 11.0% from the October 31st total of 423,400 shares. Based on an average daily trading volume, of 174,100 shares, the days-to-cover ratio is presently 2.2 days.
View ANI Pharmaceuticals' Short Interest
.

When is ANI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our ANIP earnings forecast
.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) posted its quarterly earnings results on Wednesday, November, 8th. The specialty pharmaceutical company reported $1.27 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.43. The specialty pharmaceutical company earned $131.83 million during the quarter, compared to the consensus estimate of $111.92 million. ANI Pharmaceuticals had a trailing twelve-month return on equity of 17.96% and a net margin of 2.98%. The company's revenue was up 57.3% compared to the same quarter last year. During the same period last year, the firm posted $0.46 EPS.

What ETFs hold ANI Pharmaceuticals' stock?

ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, October, 5th. The company provided EPS guidance of $3.62-$4.11 for the period, compared to the consensus estimate of $3.97. The company issued revenue guidance of $425.00 million-$445.00 million, compared to the consensus revenue estimate of $442.97 million.

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Global Alpha Capital Management Ltd. (2.59%), William Blair Investment Management LLC (2.46%), Ranger Investment Management L.P. (2.10%), Invesco Ltd. (1.67%), AIGH Capital Management LLC (1.34%) and Ameriprise Financial Inc. (1.22%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma, Krista Davis, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends
.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ANIP) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -